Cadila Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cadila Pharmaceuticals Ltd.
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.
Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- CPL Biologicals Pvt. Ltd. (Joint Venture with Novavax)